Beyond lipids: Novel mechanisms for parenteral nutrition-associated liver disease

被引:6
作者
Wichman, Brittany E. [1 ]
Nilson, Jamie [1 ]
Govindan, Srinivas [1 ]
Chen, Alan [1 ]
Jain, Aditya [1 ]
Arun, Varsha [1 ]
Derdoy, Juana [1 ]
Krebs, Joseph [1 ]
Jain, Ajay K. [1 ]
机构
[1] St Louis Univ, Sch Med, SSM Cardinal Glennon Hosp, Dept Pediat, St Louis, MO 63104 USA
基金
美国国家卫生研究院;
关键词
enteral nutrition; Farnesoid X receptor; fibroblast growth factor-19; intestinal failure; liver disease; parenteral nutrition; ACTIVATED PROTEIN-KINASES; BILE-ACIDS; FEEDBACK-REGULATION; INTESTINAL ATROPHY; HEPATIC STEATOSIS; OBETICHOLIC ACID; EPITHELIAL-CELLS; MUCOSAL ATROPHY; METABOLIC-RATE; VITAMIN-E;
D O I
10.1002/ncp.10830
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Parenteral nutrition (PN) is a therapy that delivers essential nutrients intravenously to patients who are unable to meet their nutrition requirements via standard enteral feeding. This methodology is often referred to as PN when accompanied by minimal or no enteral nutrition (EN). Although PN is lifesaving, significant complications can arise, such as intestinal failure-associated liver disease and gut-mucosal atrophy. The exact mechanism of injury remains ill defined. This review was designed to explore the available literature related to the drivers of injury mechanisms. The Farnesoid X receptor and fibroblast growth factor 19 signaling pathway seems to play an important role in gut-systemic signaling, and its alteration during PN provides insights into mechanistic links. Central line infections also play a key role in mediating PN-associated injury. Although lipid reduction strategies, as well as the use of multicomponent lipid emulsions and vitamin E, have shown promise, the cornerstone of preventing injury is the early establishment of EN.
引用
收藏
页码:265 / 273
页数:9
相关论文
共 76 条
[1]   Mechanism linking diabetes mellitus and obesity [J].
Al-Goblan, Abdullah S. ;
Al-Alfi, Mohammed A. ;
Khan, Muhammad Z. .
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2014, 7 :587-591
[2]   Bile acid transporters: Structure, function, regulation and pathophysiological implications [J].
Alrefai, Waddah A. ;
Gill, Ravinder K. .
PHARMACEUTICAL RESEARCH, 2007, 24 (10) :1803-1823
[3]  
Ayloo Subhashini, 2018, World J Transplant, V8, P167, DOI 10.5500/wjt.v8.i5.167
[4]   Targeting xenobiotic receptors PXR and CAR in human diseases [J].
Banerjee, Monimoy ;
Robbins, Delira ;
Chen, Taosheng .
DRUG DISCOVERY TODAY, 2015, 20 (05) :618-628
[5]   Metabolic Effects of Bile Acids in the Gut in Health and Disease [J].
Boesjes, Marije ;
Brufau, Gemma .
CURRENT MEDICINAL CHEMISTRY, 2014, 21 (24) :2822-2829
[6]   Histopathology of nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Tiniakos, Dina G. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (42) :5286-5296
[7]   Total parenteral nuirition-associated liver disease [J].
Buchman, A .
JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 2002, 26 (05) :S43-S48
[8]   DIGESTIVE PHYSIOLOGY OF THE PIG SYMPOSIUM: Intestinal bile acid sensing is linked to key endocrine and metabolic signaling pathways [J].
Burrin, D. ;
Stoll, B. ;
Moore, D. .
JOURNAL OF ANIMAL SCIENCE, 2013, 91 (05) :1991-2000
[9]   Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR [J].
Carter, Beth A. ;
Taylor, Olga A. ;
Prendergast, Daniel R. ;
Zimmerman, Tracy L. ;
Von Furstenberg, Richard ;
Moore, David D. ;
Karpen, Saul J. .
PEDIATRIC RESEARCH, 2007, 62 (03) :301-306
[10]   Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats [J].
Ceulemans, Laurens J. ;
Verbeke, Len ;
Decuypere, Jean-Paul ;
Farre, Ricard ;
De Hertogh, Gert ;
Lenaerts, Kaatje ;
Jochmans, Ina ;
Monbaliu, Diethard ;
Nevens, Frederik ;
Tack, Jan ;
Laleman, Wim ;
Pirenne, Jacques .
PLOS ONE, 2017, 12 (01)